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INTRODUCTION
Metformin is the most prescribed anti-diabetic drug
in patients with type 2 diabetes mellitus (T2DM) and
hence, considered a cornerstone in the treatment of
T2DM.1 It is an anti-hyperglycaemic agent that is usually
well tolerated in most of the patients (except for mild
gastrointestinal side effects) and it is characterized by
excellent improvement in the cardiovascular morbidity
and mortality associated with T2DM.2
Due to the numerous clinical benefits associated with
metformin, some side effects with potential adverse
health effects associated with its use are usually ignored
and rarely investigated. One of such side effects is
vitamin B12 deficiency.
3, 4
Vitamin B12, also called cobalamin, is a water-soluble
vitamin involved in the optimal functioning of the
hemopoetic, neuro-cognitive and vascular systems. It
is involved in DNA synthesis, fatty acid metabolism
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and energy production.5 Vitamin B12 exerts its
physiological effects by facilitating the methylation of
homocysteine to methionine which is later activated
into S-adenosyl methionine that donates its methyl
group to methyl acceptors.6. Similarly, vitamin B12
mediates the conversion of methyl malonyl coenzyme
A (coA) to succinyl coA, a process when hindered,
results in accumulation of serum methylmalonic acid
(MMA) thereby causing defective fatty acid synthesis
of  the neuronal membranes.7
Reports have shown that there is an association
between metformin use and vitamin B12 deficiency.
3, 4
However, the mechanism through which metformin
induces vitamin B12 deficiency (VBD) in patients with
T2DM is presently unclear. Some of  the suggested
mechanisms include alteration in small bowel motility,
which stimulates bacterial overgrowth and
consequential vitamin B12 deficiency. Others include
ABSTRACT
Background: Due to the clinical benefits of  metformin, its associated side
effects such as vitamin B12 deficiency are usually overlooked and rarely
investigated.
Objective: This study was carried out to determine the serum level of  vitamin
B12 in Nigerian patients with type 2 diabetes mellitus (T2DM) on  metformin.
Methods: Serum vitamin B12 level was determined using high performance
liquid chromatography (HPLC) in 81 T2DM patients who have been on
metformin for 5 years or more. Vitamin B12 deficiency was defined as serum
concentration of <200 pg/dl, borderline deficiency as 200 – 300 pg/dl and
>300 pg/dl as normal. Differences in vitamin B12 levels between different
groups were assessed using Mann WhitneyU  test andP<0.05 was considered
as statistically significant.
Results: Vitamin B12 deficiency and borderline deficiency were recorded in
8.6% and 26.0% of  the patients respectively. Vitamin B12 level was significantly
lower in patients who have been on metformin for >10 years compared with
patients with <10 years history of  metformin use. Similarly, patients who
were on metformin at a dose of  >1000 mg/day had significantly lower
vitamin B12 level when compared with patients on <1000 mg/day.
Conclusion: Low serum vitamin B12 level is associated with longer duration
and higher dose of  metformin use. Therefore, routine determination of
vitamin B12 level in patients with T2DM on high dose of  metformin and
those with prolonged use of  metformin might help in identifying patients
that would benefit from vitamin B12 supplements.
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competitive inhibition or inactivation of vitamin B12
absorption, alteration in intrinsic factor levels and
interaction with the cubulin endocytic receptor. Also,
inhibition of the calcium dependent absorption of
vitamin B12–intrinsic factor (IF) complex at the
terminal ileum has been suggested as one of  the
mechanisms.8 ,9, 10
Although decrease in vitamin B12 levels following
metformin use typically starts as early as the 4th
month,11 clinical features of vitamin B12 deficiency
become apparent by 5 years owing to the large body
stores in the liver that are not quickly depleted.10 This
is however influenced by increasing age and dose of
metformin.12, 13
Assessment of vitamin B12 deficiency in patients with
T2DM is of clinical importance. It can present as
peripheral neuropathy and may be mistaken for
diabetic neuropathy in patients on metformin
treatment.14 Also, low vitamin B12 levels have been
reported to be associated with poor nerve conduction
velocities and poorer responses to light touch by
monofilament detection. 15 This may lead to
unnecessary use of anticonvulsants, tricyclic
antidepressants and other medications for diabetic
neuropathy.14, 16, 17
Usually, the established clinical benefits of  metformin
use in patients with type 2 diabetes mellitus (T2DM)
make its side effects to be overlooked and rarely
investigated especially, in Nigeria. This study was
therefore, carried out to evaluate the serum levels of
vitamin B12 in patients with T2DM on metformin.
MATERIALS AND METHODS
Subjects
A total of 81 patients with type 2 diabetes mellitus
(T2DM) within the age range of 45 to 80 years were
recruited into this cross-sectional study using a
convenient sampling method. The patients were those
attending the Endocrinology Clinic of  the Department
of Medicine and the Metabolic Research Unit of the
Department of  Chemical Pathology, University
College Hospital, Ibadan, Nigeria. All the patients were
on metformin and have been on the drug for a
minimum of  5 years.
Exclusion criteria
Patients with gastrectomy, small bowel resection, liver
disease, chronic kidney disease and thyroid disease were
excluded from this study. Also, patients with recent
intake of oral or intramuscular vitamin B12 supplement,
patients on histamine 2 receptor blocker and vegetarians
were also excluded.
Informed Consent and Ethical Approval
Participants were enrolled into this study after obtaining
a written informed consent from each of  them. Also,
an ethical approval (UI/EC/14/0119) was obtained
from the University of Ibadan/University College
Hospital Joint Ethical Committee.
Blood pressure measurement and body mass index calculation
After at least 10 minutes of rest, BP was obtained
with the patient in supine position using a Mercury
Sphygmomanometer. Height (m) was taken using a
Stadiometer. Body mass index (BMI) was calculated
as the ratio of body weight (kg) to the square of height
(m2).
Sample collection and storage
After an overnight fast of about 8-10 hours, 5 ml of
venous blood was collected from each participant and
dispensed into plain bottles. The samples were allowed
to retract and then spun at 4000 rpm for 10 minutes
to obtain serum samples which were kept at -200C
until analysed for vitamin B12 level.
Determination of serum vitamin B12 level
Serum vitamin B12 levels of the patients were
determined using high performance liquid
chromatography (HPLC). Vitamin B12 deficiency was
defined as serum concentration of <200 pg/dl and
borderline deficiency as 200–300 pg/dl. 18
Concentrations >300 pg/dl were considered as
normal.
Statistical analysis
The distribution of vitamin B 12 levels and the
characteristics of the patients were assessed using
histogram with normal curve. Thereafter, Student’s t-
tests and Mann-Whitney U were used to determine
differences in means or medians of the variables as
appropriate. Data with Gaussian distribution are
presented as mean ± standard deviation while data
with non-Gaussian distribution are presented as
median (interquartile range). P-values less than 0.05 were
considered to be statistically significant. All analyses
were performed using SPSS (version 20.0).
RESULTS
Vitamin B12 deficiency and borderline deficiency were
respectively observed in 8.6% and 26.0% of  the
patients. About 65.4% of  the patients were not
deficient of vitamin B12.
Based on duration of  metformin use, all the patients
were divided into 2 groups: <10 years and >10 years.
As shown in Table 1, the median vitamin B12 level was
significantly lower in participants who have used
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metformin for >10 years compared with patients who
have used metformin for  <10 years.
Similarly, patients were divided into 2 groups based
on metformin dose. It was observed that the median
level of vitamin B12 was significantly lower in patients
who were on metformin at a dose of  >1000 mg/
day  compared with patients who were on metformin
at a dose of <1000 mg/day. In contrast, the mean
body weight and BMI were significantly higher in
patients who were on metformin at a dose of  >1000
mg/day compared with patients who were on
metformin at a dose of <1000 mg/day (Table 2).
DISCUSSION
Reports have shown that metformin use have a
significant impact on the concentration of vitamin B12
in patients with T2DM.19,20, 21 The percentages of
patients with vitamin B12 deficiency and with borderline
deficiency observed in this study are in line with the
report of  Nervo et al.22 This observation could be an
indication of nutritional deficiency or a consequence
of  metformin use.
The observed lower level of  vitamin B12 in patients
with T2DM who have been on metformin for 10
years or more compared with patients with <10 years
history of  metformin use corroborates earlier studies.12,
21, 23, 24 De jager et al.13 showed that the negative impact
of  metformin use on vitamin B12 level becomes
profound with increasing years of  metformin use. This
observation has been attributed to either or a
combination of alteration in small bowel motility
(which stimulates bacterial overgrowth with
<10years (n = 50 ) >10years (n = 31 ) P - value
Age (years) 60.76 ± 8.26 63.90 ± 7.94 0.095
Height (m) 1.62 ± 0.09 1.61 ± 0.08 0.851
Body weight (kg) 67.74 ± 11.47 69.10 ± 10.82 0.599
Systolic BP (mmHg) 126.00 ± 16.78 127.10 ± 16.77 0.776
Diastolic BP (mmHg) 76.24 ± 10.02 74.52 ± 11.21 0.474
BMI (kg/m2) 25.89 ± 4.00 26.45 ± 3.10 0.512
Vitamin B12 (pg/dl) 429.48 (304.17 – 510.42) 299.63 (261.12 – 373.05) 0.004*
Table 1: Characteristics of  the patients and serum levels of  vitamin B12 based on duration of  metformin use
<1000mg/day (n = 56) >1000mg/day (n = 25) P - value
Age (years) 61.96 ± 8.06 61.96 ± 8.78 0.998
Height (m) 1.61 ± 0.09 1.62 ± 0.07 0.607
Body weight (kg) 65.84 ± 9.48 73.68 ± 12.89 0.003*
Systolic BP (mmHg) 127.86 ± 16.15 123.20 ± 17.73 0.248
Diastolic BP (mmHg) 75.04 ± 9.67 76.80 ± 12.15 0.486
BMI (kg/m2) 25.30 ± 3.01 27.91 ± 4.39 0.002*
Vitamin B12 (pg/dl) 417.29 (295.94 – 505.49) 306.98 (244.22 – 389.36) 0.004*
Table 2: Characteristics of  the patients and serum levels of  vitamin B12 based on metformin dose
consequential vitamin B12 deficiency), alteration in
intrinsic factor levels, interaction with the cubulin
endocytic receptor and inhibition of the calcium
dependent absorption of vitamin B12-intrinsic factor
complex at the terminal ileum.8, 10, 11 Also, our
observation could indicate depletion in the liver vitamin
B12 store, secondary to increased duration of
metformin use.
It has been shown that each 1g daily intake of
metformin caused a ratio of  2.88 increase in the risk
of  developing vitamin B12 deficiency.
12 This possibly
explains our observed lower level of  vitamin B12 level
in patients taking more than 1000mg of  metformin
per day compared with patients on 1000mg or less
dose of  metformin per day. Several other studies have
also reported similar findings.13, 25, 26 Although the
mechanism through which high dose of  metformin
causes vitamin B12 deficiency is presently not well
understood, our observation probably indicates that
there is heightened inhibition of vitamin B12 absorption
which could cause rapid depletion of the liver store
of vitamin B12 in patients taking high dose of
metformin.
An association between obesity and poor glycaemic
control has been reported.27 Nagrebetsky et al.28
showed that there is a significant association between
lower BMI and lower glycated haemoglobin (HbA1c)
concentration, an index of glycaemic control. These
reports could explain the observed higher BMI in
patients on high dose (>1000 mg/day) of  metformin
compared with patients on low dose. This observation
                                                   Annals of Ibadan Postgraduate Medicine. Vol. 13 No. 2, December 2015              81
is not surprising as the relationship between obesity
and insulin resistance is well established.
Small sample size and non-inclusion of age-matched
control group are some of  the limitations of  this study.
CONCLUSION
It could be concluded from this study that low serum
vitamin B12 level is associated with longer duration and
higher dose of  metformin use. Therefore, routine
determination of  vitamin B12 level in patients with type
2 diabetes mellitus on high dose of  metformin and
those with prolonged use of  metformin might help
in identifying patients that would benefit from vitamin
B12 supplements.
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